Organization Overview
Alternative names
aldesleukin (Proleukin) (4 trials)
autologous hematopoietic stem cells (1 trial)
bevacizumab (avastin) (1 trial)
brentuximab vedotin (adcetris) (1 trial)
capecitabine (xeloda) (2 trials)
cyclophosphamide (cytoxan) (2 trials)
dacarbazine (dtic-dome) (1 trial)
docetaxel (taxotere) (4 trials)
doxorubicin (Doxil) (2 trials)
Filgrastim (neupogen) (1 trial)
fluorouracil (efudex) (3 trials)
Adenocarcinoma (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Adenosquamous (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Colorectal Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Gestational Trophoblastic Disease (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Follicular (Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Neuroblastoma (Phase 2)
Pancreatic Neoplasms (Phase 2)
Precancerous Conditions (Phase 2)
Preleukemia (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Syndrome (Phase 2)
Trophoblastic Neoplasms (Phase 2)
